Type: Contract Research Organization (CRO)
Location: Boston, MA, USA (with global operations)
Founded: 2009 (spun out from Harvard Medical School imaging research)
Website: invicro.com
Formerly: inviCRO (branding updated)
Invicro is a specialty contract research organization (CRO) providing imaging core laboratory services, quantitative image analysis, and scientific consulting for clinical trials. Founded by researchers from Harvard Medical School's Center for Morphometric Analysis, Invicro has become a leading provider of neuroimaging core lab services for neurodegeneration trials, including multiple 4R tau PET imaging programs for PSP[@invicro2024].
Invicro operates as a central imaging core for pharmaceutical companies and academic consortia, providing standardized image acquisition protocols, quality control, and centralized analysis across international multi-site trials. Their expertise in tau PET quantification has made them a key partner in PSP therapeutic development programs.
Invicro specializes in neuroimaging for:
Invicro serves as the imaging core for the first-in-human study of novel 4R tau-selective PET radioligands (ABBV-964i and ABBV-965i) in PSP patients[@trial2024]. Their role includes:
Invicro has contributed to standardization efforts for tau PET imaging in PSP:
While Ferrer leads the PROSPER Phase 2 trial of FNP-223 in PSP (NCT06355531), Invicro has provided imaging consultation for related tau biomarker studies, contributing to the development of OGA inhibitor imaging endpoints[@ferrer2025].
| Trial | Sponsor | Role |
|---|---|---|
| First-in-Human 4R Tau Ligand (NCT07348276) | Invicro (as sponsor) | Full imaging core lab |
| PI-2620 Tau PET (NCT04715750) | Life Molecular Imaging | Quantitative analysis |
| Biomarkers in Parkinsonian Syndromes (NCT06501469) | Academic consortium | Imaging consultation |
Invicro operates under the IXICO Technologies umbrella following acquisition, combining IXICO's digital biomarker expertise with Invicro's imaging core capabilities[@ixico2023]. This integration provides: